Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

h and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... NANONEX CORPORATION, a pioneer and leading company ... successful delivery and installation of a new nanoimprint ... major Japanese manufacturing company. , ... lithography tool that has the ability to process ... types. Based on Nanonex inventions and proprietary technologies, ...
(Date:5/21/2013)... 21, 2013 SoundConnect is pleased to ... Lync, for customers in Canada. Lync is the ... will allow businesses and organizations to collaborate and communicate ... released Lync in the United States. With the progressive ... product release in Canada, SoundConnect now offers a complete ...
(Date:5/20/2013)... 2013 , Collaboration with ... (ARS) in treatment of mastitis , ... Trials to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will ... Research Service (ARS) to develop and trial products targeting ...
(Date:5/20/2013)... , May 20, 2013 Today, at ... San Francisco , James McGough ... Psychiatry at the Semel Institute for Neuroscience and Human ... of Medicine at the University of California Los Angeles ... Child and Adolescent Psychopharmacology and ADHD at UCLA, presented ...
Breaking Biology Technology:Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3Phosphagenics Signs Research Agreement with the Agricultural Research Service 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5
... Audio Webcast Tuesday, September 11, 2007, SAN DIEGO, ... announced today that Neurocrine Biosciences will,present at the Bear ... 11, 2007 at 10:30 a.m. Eastern Time (ET),/7:30 a.m. ... may be accessed on the Company,s website at, http://www.neurocrine.com ...
... that NKTR-118 Shows Promise for the Treatment of Opioid ... ... Calif., Sept. 10 Nektar,Therapeutics (Nasdaq: NKTR ) presented ... San Francisco, California from a,Phase 1 trial of NKTR-118 (oral ...
... BioStorage Technologies, Inc.,(BST) announced that it has ... (IPL) to purchase electricity generated by 100 percent,renewable ... By offsetting the use of fossil-fueled power generation, ... carbon-neutral by 2009. BST becomes the third-largest ...
Cached Biology Technology:Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 2Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 3Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 4Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 5BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 2BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 3BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 4
(Date:5/21/2013)... shows that the nation,s land and water resources could ... up to 25 billion gallons of algae-based fuel a ... yearly needs. , The findings come from an in-depth ... to grow significant amounts of algae in large, specially ... May 7 issue of Environmental Science and Technology ...
(Date:5/21/2013)... Mo. Cancers of all types become most deadly ... Once cancer has reached this stage, it becomes very ... tumors that can develop. Now, researchers at the University ... nanoparticles that target lymphoma tumor cells wherever they may ... of oncology in the MU College of Veterinary Medicine, ...
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4MU researchers develop radioactive nanoparticles that target cancer cells 2Fueling fitness on the final frontier 2
... means Kansas State University ecologists will get more help ... opportunities for eight to 10 undergraduate students each summer ... Jumpponen, associate professors of biology, and Bruce Snyder, instructor ... National Science Foundation to help K-State continue to be ...
... Aug. 26 An exploration of the molecular links between ... for diabetes treatment, say scientists at the John G. Rangos ... findings were published earlier this month in the online version ... American Diabetes Association. Signs of low-grade systemic inflammation ...
... are increasingly offering genetic tests directly to consumers to assess ... These tests have raised concerns over whether people will receive ... by health care providers -- and whether consumers, genetic information ... On Aug. 31 and Sept. 1 the National Research ...
Cached Biology News:Pitt study finds molecular link between insulin resistance and inflammation 2
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
... System is used in conjunction ... PCR of problematic and/or GC-rich ... Solution with 10X PCRX Amplification ... broader magnesium concentration broader annealing ...
Biology Products: